#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0164] The various display methods and ELISA assays can be used to screen for shuffled antigens with improved properties such as presentation of multiple epitopes, improved immunogenicity, increased expression levels, increased folding rates and efficiency, increased stability to factors such as temperature, buffers, solvents, improved purification properties, etc.
1-1	0-1	[	_	_	
1-2	1-5	0164	_	_	
1-3	5-6	]	_	_	
1-4	7-10	The	_	_	
1-5	11-18	various	_	_	
1-6	19-26	display	_	_	
1-7	27-34	methods	_	_	
1-8	35-38	and	_	_	
1-9	39-44	ELISA	_	_	
1-10	45-51	assays	_	_	
1-11	52-55	can	_	_	
1-12	56-58	be	_	_	
1-13	59-63	used	_	_	
1-14	64-66	to	_	_	
1-15	67-73	screen	_	_	
1-16	74-77	for	_	_	
1-17	78-86	shuffled	_	_	
1-18	87-95	antigens	_	_	
1-19	96-100	with	_	_	
1-20	101-109	improved	_	_	
1-21	110-120	properties	_	_	
1-22	121-125	such	_	_	
1-23	126-128	as	_	_	
1-24	129-141	presentation	_	_	
1-25	142-144	of	_	_	
1-26	145-153	multiple	_	_	
1-27	154-162	epitopes	_	_	
1-28	162-163	,	_	_	
1-29	164-172	improved	_	_	
1-30	173-187	immunogenicity	*	_	
1-31	187-188	,	_	_	
1-32	189-198	increased	_	_	
1-33	199-209	expression	*	1-30	
1-34	210-216	levels	_	_	
1-35	216-217	,	_	_	
1-36	218-227	increased	_	_	
1-37	228-235	folding	_	_	
1-38	236-241	rates	_	_	
1-39	242-245	and	_	_	
1-40	246-256	efficiency	_	_	
1-41	256-257	,	_	_	
1-42	258-267	increased	_	_	
1-43	268-277	stability	_	_	
1-44	278-280	to	_	_	
1-45	281-288	factors	_	_	
1-46	289-293	such	_	_	
1-47	294-296	as	_	_	
1-48	297-308	temperature	_	_	
1-49	308-309	,	_	_	
1-50	310-317	buffers	_	_	
1-51	317-318	,	_	_	
1-52	319-327	solvents	_	_	
1-53	327-328	,	_	_	
1-54	329-337	improved	_	_	
1-55	338-350	purification	_	_	
1-56	351-361	properties	_	_	
1-57	361-362	,	_	_	
1-58	363-366	etc	_	_	
1-59	366-367	.	_	_	

#Text=Selection of shuffled antigens with improved expression, folding, stability and purification profile under a variety of chromatographic conditions can be very important improvements to incorporate for the vaccine manufacturing process.
#Text=[0165] To identify recombinant antigenic polypeptides that exhibit improved expression in a host cell, flow cytometry is a useful technique.
2-1	368-377	Selection	_	_	
2-2	378-380	of	_	_	
2-3	381-389	shuffled	_	_	
2-4	390-398	antigens	_	_	
2-5	399-403	with	_	_	
2-6	404-412	improved	_	_	
2-7	413-423	expression	_	_	
2-8	423-424	,	_	_	
2-9	425-432	folding	_	_	
2-10	432-433	,	_	_	
2-11	434-443	stability	_	_	
2-12	444-447	and	_	_	
2-13	448-460	purification	_	_	
2-14	461-468	profile	_	_	
2-15	469-474	under	_	_	
2-16	475-476	a	_	_	
2-17	477-484	variety	_	_	
2-18	485-487	of	_	_	
2-19	488-503	chromatographic	_	_	
2-20	504-514	conditions	_	_	
2-21	515-518	can	_	_	
2-22	519-521	be	_	_	
2-23	522-526	very	_	_	
2-24	527-536	important	_	_	
2-25	537-549	improvements	_	_	
2-26	550-552	to	_	_	
2-27	553-564	incorporate	_	_	
2-28	565-568	for	_	_	
2-29	569-572	the	_	_	
2-30	573-580	vaccine	_	_	
2-31	581-594	manufacturing	_	_	
2-32	595-602	process	_	_	
2-33	602-603	.	_	_	
2-34	604-605	[	_	_	
2-35	605-609	0165	_	_	
2-36	609-610	]	_	_	
2-37	611-613	To	_	_	
2-38	614-622	identify	_	_	
2-39	623-634	recombinant	_	_	
2-40	635-644	antigenic	_	_	
2-41	645-657	polypeptides	_	_	
2-42	658-662	that	_	_	
2-43	663-670	exhibit	_	_	
2-44	671-679	improved	_	_	
2-45	680-690	expression	_	_	
2-46	691-693	in	_	_	
2-47	694-695	a	_	_	
2-48	696-700	host	_	_	
2-49	701-705	cell	_	_	
2-50	705-706	,	_	_	
2-51	707-711	flow	_	_	
2-52	712-721	cytometry	_	_	
2-53	722-724	is	_	_	
2-54	725-726	a	_	_	
2-55	727-733	useful	_	_	
2-56	734-743	technique	_	_	
2-57	743-744	.	_	_	

#Text=Flow cytometry provides a method to efficiently analyze the functional properties of millions of individual cells.
3-1	745-749	Flow	_	_	
3-2	750-759	cytometry	_	_	
3-3	760-768	provides	_	_	
3-4	769-770	a	_	_	
3-5	771-777	method	_	_	
3-6	778-780	to	_	_	
3-7	781-792	efficiently	_	_	
3-8	793-800	analyze	_	_	
3-9	801-804	the	_	_	
3-10	805-815	functional	_	_	
3-11	816-826	properties	_	_	
3-12	827-829	of	_	_	
3-13	830-838	millions	_	_	
3-14	839-841	of	_	_	
3-15	842-852	individual	_	_	
3-16	853-858	cells	_	_	
3-17	858-859	.	_	_	

#Text=One can analyze the expression levels of several genes simultaneously, and flow cytometry-based cell sorting allows for the selection of cells that display properly expressed antigen variants on the cell surface or in the cytoplasm.
4-1	860-863	One	_	_	
4-2	864-867	can	_	_	
4-3	868-875	analyze	_	_	
4-4	876-879	the	_	_	
4-5	880-890	expression	_	_	
4-6	891-897	levels	_	_	
4-7	898-900	of	_	_	
4-8	901-908	several	_	_	
4-9	909-914	genes	_	_	
4-10	915-929	simultaneously	_	_	
4-11	929-930	,	_	_	
4-12	931-934	and	_	_	
4-13	935-939	flow	_	_	
4-14	940-955	cytometry-based	_	_	
4-15	956-960	cell	_	_	
4-16	961-968	sorting	_	_	
4-17	969-975	allows	_	_	
4-18	976-979	for	_	_	
4-19	980-983	the	_	_	
4-20	984-993	selection	_	_	
4-21	994-996	of	_	_	
4-22	997-1002	cells	_	_	
4-23	1003-1007	that	_	_	
4-24	1008-1015	display	_	_	
4-25	1016-1024	properly	_	_	
4-26	1025-1034	expressed	_	_	
4-27	1035-1042	antigen	_	_	
4-28	1043-1051	variants	_	_	
4-29	1052-1054	on	_	_	
4-30	1055-1058	the	_	_	
4-31	1059-1063	cell	_	_	
4-32	1064-1071	surface	_	_	
4-33	1072-1074	or	_	_	
4-34	1075-1077	in	_	_	
4-35	1078-1081	the	_	_	
4-36	1082-1091	cytoplasm	_	_	
4-37	1091-1092	.	_	_	

#Text=Very large numbers (>10.sup.7) of cells can be evaluated in a single vial experiment, and the pool of the best individual sequences can be recovered from the sorted cells.
5-1	1093-1097	Very	_	_	
5-2	1098-1103	large	_	_	
5-3	1104-1111	numbers	_	_	
5-4	1112-1113	(	_	_	
5-5	1113-1114	>	_	_	
5-6	1114-1116	10	_	_	
5-7	1116-1117	.	_	_	
5-8	1117-1120	sup	_	_	
5-9	1120-1122	.7	_	_	
5-10	1122-1123	)	_	_	
5-11	1124-1126	of	_	_	
5-12	1127-1132	cells	_	_	
5-13	1133-1136	can	_	_	
5-14	1137-1139	be	_	_	
5-15	1140-1149	evaluated	_	_	
5-16	1150-1152	in	_	_	
5-17	1153-1154	a	_	_	
5-18	1155-1161	single	_	_	
5-19	1162-1166	vial	_	_	
5-20	1167-1177	experiment	_	_	
5-21	1177-1178	,	_	_	
5-22	1179-1182	and	_	_	
5-23	1183-1186	the	_	_	
5-24	1187-1191	pool	_	_	
5-25	1192-1194	of	_	_	
5-26	1195-1198	the	_	_	
5-27	1199-1203	best	_	_	
5-28	1204-1214	individual	_	_	
5-29	1215-1224	sequences	_	_	
5-30	1225-1228	can	_	_	
5-31	1229-1231	be	_	_	
5-32	1232-1241	recovered	_	_	
5-33	1242-1246	from	_	_	
5-34	1247-1250	the	_	_	
5-35	1251-1257	sorted	_	_	
5-36	1258-1263	cells	_	_	
5-37	1263-1264	.	_	_	

#Text=These methods are particularly useful in the case of, for example, Hantaan virus glycoproteins, which are generally very poorly expressed in mammalian cells.
6-1	1265-1270	These	_	_	
6-2	1271-1278	methods	_	_	
6-3	1279-1282	are	_	_	
6-4	1283-1295	particularly	_	_	
6-5	1296-1302	useful	_	_	
6-6	1303-1305	in	_	_	
6-7	1306-1309	the	_	_	
6-8	1310-1314	case	_	_	
6-9	1315-1317	of	_	_	
6-10	1317-1318	,	_	_	
6-11	1319-1322	for	_	_	
6-12	1323-1330	example	_	_	
6-13	1330-1331	,	_	_	
6-14	1332-1339	Hantaan	_	_	
6-15	1340-1345	virus	_	_	
6-16	1346-1359	glycoproteins	_	_	
6-17	1359-1360	,	_	_	
6-18	1361-1366	which	_	_	
6-19	1367-1370	are	_	_	
6-20	1371-1380	generally	_	_	
6-21	1381-1385	very	_	_	
6-22	1386-1392	poorly	_	_	
6-23	1393-1402	expressed	_	_	
6-24	1403-1405	in	_	_	
6-25	1406-1415	mammalian	_	_	
6-26	1416-1421	cells	_	_	
6-27	1421-1422	.	_	_	

#Text=This approach provides a general solution to improve expression levels of pathogen antigens in mammalian cells, a phenomenon that is critical for the function of genetic vaccines.
#Text=[0166] To use flow cytometry to analyze polypeptides that are not expressed on the cell surface, one can engineer the recombinant polynucleotides in the library such that the polynucleotide is expressed as a fusion protein that has a region of amino acids which is targeted to the cell membrane.
7-1	1423-1427	This	_	_	
7-2	1428-1436	approach	_	_	
7-3	1437-1445	provides	_	_	
7-4	1446-1447	a	_	_	
7-5	1448-1455	general	_	_	
7-6	1456-1464	solution	_	_	
7-7	1465-1467	to	_	_	
7-8	1468-1475	improve	_	_	
7-9	1476-1486	expression	_	_	
7-10	1487-1493	levels	_	_	
7-11	1494-1496	of	_	_	
7-12	1497-1505	pathogen	_	_	
7-13	1506-1514	antigens	_	_	
7-14	1515-1517	in	_	_	
7-15	1518-1527	mammalian	_	_	
7-16	1528-1533	cells	_	_	
7-17	1533-1534	,	_	_	
7-18	1535-1536	a	_	_	
7-19	1537-1547	phenomenon	_	_	
7-20	1548-1552	that	_	_	
7-21	1553-1555	is	_	_	
7-22	1556-1564	critical	_	_	
7-23	1565-1568	for	_	_	
7-24	1569-1572	the	_	_	
7-25	1573-1581	function	_	_	
7-26	1582-1584	of	_	_	
7-27	1585-1592	genetic	_	_	
7-28	1593-1601	vaccines	_	_	
7-29	1601-1602	.	_	_	
7-30	1603-1604	[	_	_	
7-31	1604-1608	0166	_	_	
7-32	1608-1609	]	_	_	
7-33	1610-1612	To	_	_	
7-34	1613-1616	use	_	_	
7-35	1617-1621	flow	_	_	
7-36	1622-1631	cytometry	_	_	
7-37	1632-1634	to	_	_	
7-38	1635-1642	analyze	_	_	
7-39	1643-1655	polypeptides	_	_	
7-40	1656-1660	that	_	_	
7-41	1661-1664	are	_	_	
7-42	1665-1668	not	_	_	
7-43	1669-1678	expressed	_	_	
7-44	1679-1681	on	_	_	
7-45	1682-1685	the	_	_	
7-46	1686-1690	cell	_	_	
7-47	1691-1698	surface	_	_	
7-48	1698-1699	,	_	_	
7-49	1700-1703	one	_	_	
7-50	1704-1707	can	_	_	
7-51	1708-1716	engineer	_	_	
7-52	1717-1720	the	_	_	
7-53	1721-1732	recombinant	_	_	
7-54	1733-1748	polynucleotides	_	_	
7-55	1749-1751	in	_	_	
7-56	1752-1755	the	_	_	
7-57	1756-1763	library	_	_	
7-58	1764-1768	such	_	_	
7-59	1769-1773	that	_	_	
7-60	1774-1777	the	_	_	
7-61	1778-1792	polynucleotide	_	_	
7-62	1793-1795	is	_	_	
7-63	1796-1805	expressed	_	_	
7-64	1806-1808	as	_	_	
7-65	1809-1810	a	_	_	
7-66	1811-1817	fusion	_	_	
7-67	1818-1825	protein	_	_	
7-68	1826-1830	that	_	_	
7-69	1831-1834	has	_	_	
7-70	1835-1836	a	_	_	
7-71	1837-1843	region	_	_	
7-72	1844-1846	of	_	_	
7-73	1847-1852	amino	_	_	
7-74	1853-1858	acids	_	_	
7-75	1859-1864	which	_	_	
7-76	1865-1867	is	_	_	
7-77	1868-1876	targeted	_	_	
7-78	1877-1879	to	_	_	
7-79	1880-1883	the	_	_	
7-80	1884-1888	cell	_	_	
7-81	1889-1897	membrane	_	_	
7-82	1897-1898	.	_	_	

#Text=For example, the region can encode a hydrophobic stretch of C-terminal amino acids which signals the attachment of a phosphoinositol-glycan (PIG) terminus on the expressed protein and directs the protein to be expressed on the surface of the transfected cell (Whitehom et al. (1995) Biotechnology (N Y) 13:1215-9).
8-1	1899-1902	For	_	_	
8-2	1903-1910	example	_	_	
8-3	1910-1911	,	_	_	
8-4	1912-1915	the	_	_	
8-5	1916-1922	region	_	_	
8-6	1923-1926	can	_	_	
8-7	1927-1933	encode	_	_	
8-8	1934-1935	a	_	_	
8-9	1936-1947	hydrophobic	_	_	
8-10	1948-1955	stretch	_	_	
8-11	1956-1958	of	_	_	
8-12	1959-1969	C-terminal	_	_	
8-13	1970-1975	amino	_	_	
8-14	1976-1981	acids	_	_	
8-15	1982-1987	which	_	_	
8-16	1988-1995	signals	_	_	
8-17	1996-1999	the	_	_	
8-18	2000-2010	attachment	_	_	
8-19	2011-2013	of	_	_	
8-20	2014-2015	a	_	_	
8-21	2016-2038	phosphoinositol-glycan	_	_	
8-22	2039-2040	(	_	_	
8-23	2040-2043	PIG	_	_	
8-24	2043-2044	)	_	_	
8-25	2045-2053	terminus	_	_	
8-26	2054-2056	on	_	_	
8-27	2057-2060	the	_	_	
8-28	2061-2070	expressed	_	_	
8-29	2071-2078	protein	_	_	
8-30	2079-2082	and	_	_	
8-31	2083-2090	directs	_	_	
8-32	2091-2094	the	_	_	
8-33	2095-2102	protein	_	_	
8-34	2103-2105	to	_	_	
8-35	2106-2108	be	_	_	
8-36	2109-2118	expressed	_	_	
8-37	2119-2121	on	_	_	
8-38	2122-2125	the	_	_	
8-39	2126-2133	surface	_	_	
8-40	2134-2136	of	_	_	
8-41	2137-2140	the	_	_	
8-42	2141-2152	transfected	_	_	
8-43	2153-2157	cell	_	_	
8-44	2158-2159	(	_	_	
8-45	2159-2167	Whitehom	_	_	
8-46	2168-2170	et	_	_	
8-47	2171-2173	al	_	_	
8-48	2173-2174	.	_	_	
8-49	2175-2176	(	_	_	
8-50	2176-2180	1995	_	_	
8-51	2180-2181	)	_	_	
8-52	2182-2195	Biotechnology	_	_	
8-53	2196-2197	(	_	_	
8-54	2197-2198	N	_	_	
8-55	2199-2200	Y	_	_	
8-56	2200-2201	)	_	_	
8-57	2202-2204	13	_	_	
8-58	2204-2205	:	_	_	
8-59	2205-2209	1215	_	_	
8-60	2209-2210	-	_	_	
8-61	2210-2211	9	_	_	
8-62	2211-2212	)	_	_	
8-63	2212-2213	.	_	_	

#Text=With an antigen that is naturally a soluble protein, this method will likely not affect the three dimensional folding of the protein in this engineered fusion with a new C-terminus.
9-1	2214-2218	With	_	_	
9-2	2219-2221	an	_	_	
9-3	2222-2229	antigen	_	_	
9-4	2230-2234	that	_	_	
9-5	2235-2237	is	_	_	
9-6	2238-2247	naturally	_	_	
9-7	2248-2249	a	_	_	
9-8	2250-2257	soluble	_	_	
9-9	2258-2265	protein	_	_	
9-10	2265-2266	,	_	_	
9-11	2267-2271	this	_	_	
9-12	2272-2278	method	_	_	
9-13	2279-2283	will	_	_	
9-14	2284-2290	likely	_	_	
9-15	2291-2294	not	_	_	
9-16	2295-2301	affect	_	_	
9-17	2302-2305	the	_	_	
9-18	2306-2311	three	_	_	
9-19	2312-2323	dimensional	_	_	
9-20	2324-2331	folding	_	_	
9-21	2332-2334	of	_	_	
9-22	2335-2338	the	_	_	
9-23	2339-2346	protein	_	_	
9-24	2347-2349	in	_	_	
9-25	2350-2354	this	_	_	
9-26	2355-2365	engineered	_	_	
9-27	2366-2372	fusion	_	_	
9-28	2373-2377	with	_	_	
9-29	2378-2379	a	_	_	
9-30	2380-2383	new	_	_	
9-31	2384-2394	C-terminus	_	_	
9-32	2394-2395	.	_	_	

#Text=With an antigen that is naturally a transmembrane protein (e.g., a surface membrane protein on pathogenic viruses, bacteria, protozoa or tumor cells) there are at least two possibilities.
10-1	2396-2400	With	_	_	
10-2	2401-2403	an	_	_	
10-3	2404-2411	antigen	_	_	
10-4	2412-2416	that	_	_	
10-5	2417-2419	is	_	_	
10-6	2420-2429	naturally	_	_	
10-7	2430-2431	a	_	_	
10-8	2432-2445	transmembrane	_	_	
10-9	2446-2453	protein	_	_	
10-10	2454-2455	(	_	_	
10-11	2455-2458	e.g	_	_	
10-12	2458-2459	.	_	_	
10-13	2459-2460	,	_	_	
10-14	2461-2462	a	_	_	
10-15	2463-2470	surface	_	_	
10-16	2471-2479	membrane	_	_	
10-17	2480-2487	protein	_	_	
10-18	2488-2490	on	_	_	
10-19	2491-2501	pathogenic	_	_	
10-20	2502-2509	viruses	_	_	
10-21	2509-2510	,	_	_	
10-22	2511-2519	bacteria	_	_	
10-23	2519-2520	,	_	_	
10-24	2521-2529	protozoa	_	_	
10-25	2530-2532	or	_	_	
10-26	2533-2538	tumor	_	_	
10-27	2539-2544	cells	_	_	
10-28	2544-2545	)	_	_	
10-29	2546-2551	there	_	_	
10-30	2552-2555	are	_	_	
10-31	2556-2558	at	_	_	
10-32	2559-2564	least	_	_	
10-33	2565-2568	two	_	_	
10-34	2569-2582	possibilities	_	_	
10-35	2582-2583	.	_	_	

#Text=First, the extracellular domain can be engineered to be in fusion with the C-terminal sequence for signaling PIG-linkage.
11-1	2584-2589	First	_	_	
11-2	2589-2590	,	_	_	
11-3	2591-2594	the	_	_	
11-4	2595-2608	extracellular	_	_	
11-5	2609-2615	domain	_	_	
11-6	2616-2619	can	_	_	
11-7	2620-2622	be	_	_	
11-8	2623-2633	engineered	_	_	
11-9	2634-2636	to	_	_	
11-10	2637-2639	be	_	_	
11-11	2640-2642	in	_	_	
11-12	2643-2649	fusion	_	_	
11-13	2650-2654	with	_	_	
11-14	2655-2658	the	_	_	
11-15	2659-2669	C-terminal	_	_	
11-16	2670-2678	sequence	_	_	
11-17	2679-2682	for	_	_	
11-18	2683-2692	signaling	_	_	
11-19	2693-2704	PIG-linkage	_	_	
11-20	2704-2705	.	_	_	

#Text=Second, the protein can be expressed in toto relying on the signalling of the host cell to direct it efficiently to the cell surface.
12-1	2706-2712	Second	_	_	
12-2	2712-2713	,	_	_	
12-3	2714-2717	the	_	_	
12-4	2718-2725	protein	_	_	
12-5	2726-2729	can	_	_	
12-6	2730-2732	be	_	_	
12-7	2733-2742	expressed	_	_	
12-8	2743-2745	in	_	_	
12-9	2746-2750	toto	_	_	
12-10	2751-2758	relying	_	_	
12-11	2759-2761	on	_	_	
12-12	2762-2765	the	_	_	
12-13	2766-2776	signalling	_	_	
12-14	2777-2779	of	_	_	
12-15	2780-2783	the	_	_	
12-16	2784-2788	host	_	_	
12-17	2789-2793	cell	_	_	
12-18	2794-2796	to	_	_	
12-19	2797-2803	direct	_	_	
12-20	2804-2806	it	_	_	
12-21	2807-2818	efficiently	_	_	
12-22	2819-2821	to	_	_	
12-23	2822-2825	the	_	_	
12-24	2826-2830	cell	_	_	
12-25	2831-2838	surface	_	_	
12-26	2838-2839	.	_	_	

#Text=In a minority of cases, the antigen for expression will have an endogenous PIG terminal linkage (e.g., some antigens of pathogenic protozoa).
#Text=[0167] Those cells expressing the antigen can be identified with a fluorescent monoclonal antibody specific for the C-terminal sequence on PIG-linked forms of the surface antigen.
13-1	2840-2842	In	_	_	
13-2	2843-2844	a	_	_	
13-3	2845-2853	minority	_	_	
13-4	2854-2856	of	_	_	
13-5	2857-2862	cases	_	_	
13-6	2862-2863	,	_	_	
13-7	2864-2867	the	_	_	
13-8	2868-2875	antigen	_	_	
13-9	2876-2879	for	_	_	
13-10	2880-2890	expression	_	_	
13-11	2891-2895	will	_	_	
13-12	2896-2900	have	_	_	
13-13	2901-2903	an	_	_	
13-14	2904-2914	endogenous	_	_	
13-15	2915-2918	PIG	_	_	
13-16	2919-2927	terminal	_	_	
13-17	2928-2935	linkage	_	_	
13-18	2936-2937	(	_	_	
13-19	2937-2940	e.g	_	_	
13-20	2940-2941	.	_	_	
13-21	2941-2942	,	_	_	
13-22	2943-2947	some	_	_	
13-23	2948-2956	antigens	_	_	
13-24	2957-2959	of	_	_	
13-25	2960-2970	pathogenic	_	_	
13-26	2971-2979	protozoa	_	_	
13-27	2979-2980	)	_	_	
13-28	2980-2981	.	_	_	
13-29	2982-2983	[	_	_	
13-30	2983-2987	0167	_	_	
13-31	2987-2988	]	_	_	
13-32	2989-2994	Those	_	_	
13-33	2995-3000	cells	_	_	
13-34	3001-3011	expressing	_	_	
13-35	3012-3015	the	_	_	
13-36	3016-3023	antigen	_	_	
13-37	3024-3027	can	_	_	
13-38	3028-3030	be	_	_	
13-39	3031-3041	identified	_	_	
13-40	3042-3046	with	_	_	
13-41	3047-3048	a	_	_	
13-42	3049-3060	fluorescent	_	_	
13-43	3061-3071	monoclonal	_	_	
13-44	3072-3080	antibody	_	_	
13-45	3081-3089	specific	_	_	
13-46	3090-3093	for	_	_	
13-47	3094-3097	the	_	_	
13-48	3098-3108	C-terminal	_	_	
13-49	3109-3117	sequence	_	_	
13-50	3118-3120	on	_	_	
13-51	3121-3131	PIG-linked	_	_	
13-52	3132-3137	forms	_	_	
13-53	3138-3140	of	_	_	
13-54	3141-3144	the	_	_	
13-55	3145-3152	surface	_	_	
13-56	3153-3160	antigen	_	_	
13-57	3160-3161	.	_	_	

#Text=FACS analysis allows quantitative assessment of the level of expression of the correct form of the antigen on the cell population.
14-1	3162-3166	FACS	_	_	
14-2	3167-3175	analysis	_	_	
14-3	3176-3182	allows	_	_	
14-4	3183-3195	quantitative	_	_	
14-5	3196-3206	assessment	_	_	
14-6	3207-3209	of	_	_	
14-7	3210-3213	the	_	_	
14-8	3214-3219	level	_	_	
14-9	3220-3222	of	_	_	
14-10	3223-3233	expression	_	_	
14-11	3234-3236	of	_	_	
14-12	3237-3240	the	_	_	
14-13	3241-3248	correct	_	_	
14-14	3249-3253	form	_	_	
14-15	3254-3256	of	_	_	
14-16	3257-3260	the	_	_	
14-17	3261-3268	antigen	_	_	
14-18	3269-3271	on	_	_	
14-19	3272-3275	the	_	_	
14-20	3276-3280	cell	_	_	
14-21	3281-3291	population	_	_	
14-22	3291-3292	.	_	_	

#Text=Cells expressing the maximal level of antigen are sorted and standard molecular biology methods are used to recover the plasmid DNA vaccine vector that conferred this reactivity.
15-1	3293-3298	Cells	_	_	
15-2	3299-3309	expressing	_	_	
15-3	3310-3313	the	_	_	
15-4	3314-3321	maximal	_	_	
15-5	3322-3327	level	_	_	
15-6	3328-3330	of	_	_	
15-7	3331-3338	antigen	_	_	
15-8	3339-3342	are	_	_	
15-9	3343-3349	sorted	_	_	
15-10	3350-3353	and	_	_	
15-11	3354-3362	standard	_	_	
15-12	3363-3372	molecular	_	_	
15-13	3373-3380	biology	_	_	
15-14	3381-3388	methods	_	_	
15-15	3389-3392	are	_	_	
15-16	3393-3397	used	_	_	
15-17	3398-3400	to	_	_	
15-18	3401-3408	recover	_	_	
15-19	3409-3412	the	_	_	
15-20	3413-3420	plasmid	_	_	
15-21	3421-3424	DNA	_	_	
15-22	3425-3432	vaccine	_	_	
15-23	3433-3439	vector	_	_	
15-24	3440-3444	that	_	_	
15-25	3445-3454	conferred	_	_	
15-26	3455-3459	this	_	_	
15-27	3460-3470	reactivity	_	_	
15-28	3470-3471	.	_	_	

#Text=An alternative procedure that allows purification of all those cells expressing the antigen (and that may be useful prior to loading onto a cell sorter since antigen expressing cells may be a very small minority population), is to rosette or pan-purify the cells expressing surface antigen.
16-1	3472-3474	An	_	_	
16-2	3475-3486	alternative	_	_	
16-3	3487-3496	procedure	_	_	
16-4	3497-3501	that	_	_	
16-5	3502-3508	allows	_	_	
16-6	3509-3521	purification	_	_	
16-7	3522-3524	of	_	_	
16-8	3525-3528	all	_	_	
16-9	3529-3534	those	_	_	
16-10	3535-3540	cells	_	_	
16-11	3541-3551	expressing	_	_	
16-12	3552-3555	the	_	_	
16-13	3556-3563	antigen	_	_	
16-14	3564-3565	(	_	_	
16-15	3565-3568	and	_	_	
16-16	3569-3573	that	_	_	
16-17	3574-3577	may	_	_	
16-18	3578-3580	be	_	_	
16-19	3581-3587	useful	_	_	
16-20	3588-3593	prior	_	_	
16-21	3594-3596	to	_	_	
16-22	3597-3604	loading	_	_	
16-23	3605-3609	onto	_	_	
16-24	3610-3611	a	_	_	
16-25	3612-3616	cell	_	_	
16-26	3617-3623	sorter	_	_	
16-27	3624-3629	since	_	_	
16-28	3630-3637	antigen	_	_	
16-29	3638-3648	expressing	_	_	
16-30	3649-3654	cells	_	_	
16-31	3655-3658	may	_	_	
16-32	3659-3661	be	_	_	
16-33	3662-3663	a	_	_	
16-34	3664-3668	very	_	_	
16-35	3669-3674	small	_	_	
16-36	3675-3683	minority	_	_	
16-37	3684-3694	population	_	_	
16-38	3694-3695	)	_	_	
16-39	3695-3696	,	_	_	
16-40	3697-3699	is	_	_	
16-41	3700-3702	to	_	_	
16-42	3703-3710	rosette	_	_	
16-43	3711-3713	or	_	_	
16-44	3714-3724	pan-purify	_	_	
16-45	3725-3728	the	_	_	
16-46	3729-3734	cells	_	_	
16-47	3735-3745	expressing	_	_	
16-48	3746-3753	surface	_	_	
16-49	3754-3761	antigen	_	_	
16-50	3761-3762	.	_	_	

#Text=Rosettes can be formed between antigen expressing cells and erythrocytes bearing covalently coupled antibody to the relevant antigen.
17-1	3763-3771	Rosettes	_	_	
17-2	3772-3775	can	_	_	
17-3	3776-3778	be	_	_	
17-4	3779-3785	formed	_	_	
17-5	3786-3793	between	_	_	
17-6	3794-3801	antigen	_	_	
17-7	3802-3812	expressing	_	_	
17-8	3813-3818	cells	_	_	
17-9	3819-3822	and	_	_	
17-10	3823-3835	erythrocytes	_	_	
17-11	3836-3843	bearing	_	_	
17-12	3844-3854	covalently	_	_	
17-13	3855-3862	coupled	_	_	
17-14	3863-3871	antibody	_	_	
17-15	3872-3874	to	_	_	
17-16	3875-3878	the	_	_	
17-17	3879-3887	relevant	_	_	
17-18	3888-3895	antigen	_	_	
17-19	3895-3896	.	_	_	

#Text=These are readily purified by unit gravity sedimentation.
18-1	3897-3902	These	_	_	
18-2	3903-3906	are	_	_	
18-3	3907-3914	readily	_	_	
18-4	3915-3923	purified	_	_	
18-5	3924-3926	by	_	_	
18-6	3927-3931	unit	_	_	
18-7	3932-3939	gravity	_	_	
18-8	3940-3953	sedimentation	_	_	
18-9	3953-3954	.	_	_	

#Text=Panning of the cell population over petri dishes bearing immobilized monoclonal antibody specific for the relevant antigen can also be used to remove unwanted cells.
#Text=[0168] In the high throughput assays of the invention, it is possible to screen up to several thousand different shuffled variants in a single day.
19-1	3955-3962	Panning	_	_	
19-2	3963-3965	of	_	_	
19-3	3966-3969	the	_	_	
19-4	3970-3974	cell	_	_	
19-5	3975-3985	population	_	_	
19-6	3986-3990	over	_	_	
19-7	3991-3996	petri	_	_	
19-8	3997-4003	dishes	_	_	
19-9	4004-4011	bearing	_	_	
19-10	4012-4023	immobilized	_	_	
19-11	4024-4034	monoclonal	_	_	
19-12	4035-4043	antibody	_	_	
19-13	4044-4052	specific	_	_	
19-14	4053-4056	for	_	_	
19-15	4057-4060	the	_	_	
19-16	4061-4069	relevant	_	_	
19-17	4070-4077	antigen	_	_	
19-18	4078-4081	can	_	_	
19-19	4082-4086	also	_	_	
19-20	4087-4089	be	_	_	
19-21	4090-4094	used	_	_	
19-22	4095-4097	to	_	_	
19-23	4098-4104	remove	_	_	
19-24	4105-4113	unwanted	_	_	
19-25	4114-4119	cells	_	_	
19-26	4119-4120	.	_	_	
19-27	4121-4122	[	_	_	
19-28	4122-4126	0168	_	_	
19-29	4126-4127	]	_	_	
19-30	4128-4130	In	_	_	
19-31	4131-4134	the	_	_	
19-32	4135-4139	high	_	_	
19-33	4140-4150	throughput	_	_	
19-34	4151-4157	assays	_	_	
19-35	4158-4160	of	_	_	
19-36	4161-4164	the	_	_	
19-37	4165-4174	invention	_	_	
19-38	4174-4175	,	_	_	
19-39	4176-4178	it	_	_	
19-40	4179-4181	is	_	_	
19-41	4182-4190	possible	_	_	
19-42	4191-4193	to	_	_	
19-43	4194-4200	screen	_	_	
19-44	4201-4203	up	_	_	
19-45	4204-4206	to	_	_	
19-46	4207-4214	several	_	_	
19-47	4215-4223	thousand	_	_	
19-48	4224-4233	different	_	_	
19-49	4234-4242	shuffled	_	_	
19-50	4243-4251	variants	_	_	
19-51	4252-4254	in	_	_	
19-52	4255-4256	a	_	_	
19-53	4257-4263	single	_	_	
19-54	4264-4267	day	_	_	
19-55	4267-4268	.	_	_	

#Text=For example, each well of a microtiter plate can be used to run a separate assay, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single variant.
20-1	4269-4272	For	_	_	
20-2	4273-4280	example	_	_	
20-3	4280-4281	,	_	_	
20-4	4282-4286	each	_	_	
20-5	4287-4291	well	_	_	
20-6	4292-4294	of	_	_	
20-7	4295-4296	a	_	_	
20-8	4297-4307	microtiter	_	_	
20-9	4308-4313	plate	_	_	
20-10	4314-4317	can	_	_	
20-11	4318-4320	be	_	_	
20-12	4321-4325	used	_	_	
20-13	4326-4328	to	_	_	
20-14	4329-4332	run	_	_	
20-15	4333-4334	a	_	_	
20-16	4335-4343	separate	_	_	
20-17	4344-4349	assay	_	_	
20-18	4349-4350	,	_	_	
20-19	4351-4353	or	_	_	
20-20	4353-4354	,	_	_	
20-21	4355-4357	if	_	_	
20-22	4358-4371	concentration	_	_	
20-23	4372-4374	or	_	_	
20-24	4375-4385	incubation	_	_	
20-25	4386-4390	time	_	_	
20-26	4391-4398	effects	_	_	
20-27	4399-4402	are	_	_	
20-28	4403-4405	to	_	_	
20-29	4406-4408	be	_	_	
20-30	4409-4417	observed	_	_	
20-31	4417-4418	,	_	_	
20-32	4419-4424	every	_	_	
20-33	4425-4426	5	_	_	
20-34	4426-4427	-	_	_	
20-35	4427-4429	10	_	_	
20-36	4430-4435	wells	_	_	
20-37	4436-4439	can	_	_	
20-38	4440-4444	test	_	_	
20-39	4445-4446	a	_	_	
20-40	4447-4453	single	_	_	
20-41	4454-4461	variant	_	_	
20-42	4461-4462	.	_	_	

#Text=Thus, a single standard microtiter plate can assay about 100 (e.g., 96) reactions.
21-1	4463-4467	Thus	_	_	
21-2	4467-4468	,	_	_	
21-3	4469-4470	a	_	_	
21-4	4471-4477	single	_	_	
21-5	4478-4486	standard	_	_	
21-6	4487-4497	microtiter	_	_	
21-7	4498-4503	plate	_	_	
21-8	4504-4507	can	_	_	
21-9	4508-4513	assay	_	_	
21-10	4514-4519	about	_	_	
21-11	4520-4523	100	_	_	
21-12	4524-4525	(	_	_	
21-13	4525-4528	e.g	_	_	
21-14	4528-4529	.	_	_	
21-15	4529-4530	,	_	_	
21-16	4531-4533	96	_	_	
21-17	4533-4534	)	_	_	
21-18	4535-4544	reactions	_	_	
21-19	4544-4545	.	_	_	

#Text=If 1536 well plates are used, then a single plate can easily assay from about 100 to about 1500 different reactions.
22-1	4546-4548	If	_	_	
22-2	4549-4553	1536	_	_	
22-3	4554-4558	well	_	_	
22-4	4559-4565	plates	_	_	
22-5	4566-4569	are	_	_	
22-6	4570-4574	used	_	_	
22-7	4574-4575	,	_	_	
22-8	4576-4580	then	_	_	
22-9	4581-4582	a	_	_	
22-10	4583-4589	single	_	_	
22-11	4590-4595	plate	_	_	
22-12	4596-4599	can	_	_	
22-13	4600-4606	easily	_	_	
22-14	4607-4612	assay	_	_	
22-15	4613-4617	from	_	_	
22-16	4618-4623	about	_	_	
22-17	4624-4627	100	_	_	
22-18	4628-4630	to	_	_	
22-19	4631-4636	about	_	_	
22-20	4637-4641	1500	_	_	
22-21	4642-4651	different	_	_	
22-22	4652-4661	reactions	_	_	
22-23	4661-4662	.	_	_	

#Text=It is possible to assay several different plates per day; assay screens for up to about 6,000-20,000 different assays (i.e., involving different nucleic acids, encoded proteins, concentrations, etc.) is possible using the integrated systems of the invention.
23-1	4663-4665	It	_	_	
23-2	4666-4668	is	_	_	
23-3	4669-4677	possible	_	_	
23-4	4678-4680	to	_	_	
23-5	4681-4686	assay	_	_	
23-6	4687-4694	several	_	_	
23-7	4695-4704	different	_	_	
23-8	4705-4711	plates	_	_	
23-9	4712-4715	per	_	_	
23-10	4716-4719	day	_	_	
23-11	4719-4720	;	_	_	
23-12	4721-4726	assay	_	_	
23-13	4727-4734	screens	_	_	
23-14	4735-4738	for	_	_	
23-15	4739-4741	up	_	_	
23-16	4742-4744	to	_	_	
23-17	4745-4750	about	_	_	
23-18	4751-4756	6,000	_	_	
23-19	4756-4757	-	_	_	
23-20	4757-4763	20,000	_	_	
23-21	4764-4773	different	_	_	
23-22	4774-4780	assays	_	_	
23-23	4781-4782	(	_	_	
23-24	4782-4785	i.e	_	_	
23-25	4785-4786	.	_	_	
23-26	4786-4787	,	_	_	
23-27	4788-4797	involving	_	_	
23-28	4798-4807	different	_	_	
23-29	4808-4815	nucleic	_	_	
23-30	4816-4821	acids	_	_	
23-31	4821-4822	,	_	_	
23-32	4823-4830	encoded	_	_	
23-33	4831-4839	proteins	_	_	
23-34	4839-4840	,	_	_	
23-35	4841-4855	concentrations	_	_	
23-36	4855-4856	,	_	_	
23-37	4857-4860	etc	_	_	
23-38	4860-4861	.	_	_	
23-39	4861-4862	)	_	_	
23-40	4863-4865	is	_	_	
23-41	4866-4874	possible	_	_	
23-42	4875-4880	using	_	_	
23-43	4881-4884	the	_	_	
23-44	4885-4895	integrated	_	_	
23-45	4896-4903	systems	_	_	
23-46	4904-4906	of	_	_	
23-47	4907-4910	the	_	_	
23-48	4911-4920	invention	_	_	
23-49	4920-4921	.	_	_	

#Text=More recently, microfluidic approaches to reagent manipulation have been developed, e.g., by Caliper Technologies (Palo Alto, Calif.).
24-1	4922-4926	More	_	_	
24-2	4927-4935	recently	_	_	
24-3	4935-4936	,	_	_	
24-4	4937-4949	microfluidic	_	_	
24-5	4950-4960	approaches	_	_	
24-6	4961-4963	to	_	_	
24-7	4964-4971	reagent	_	_	
24-8	4972-4984	manipulation	_	_	
24-9	4985-4989	have	_	_	
24-10	4990-4994	been	_	_	
24-11	4995-5004	developed	_	_	
24-12	5004-5005	,	_	_	
24-13	5006-5009	e.g	_	_	
24-14	5009-5010	.	_	_	
24-15	5010-5011	,	_	_	
24-16	5012-5014	by	_	_	
24-17	5015-5022	Caliper	_	_	
24-18	5023-5035	Technologies	_	_	
24-19	5036-5037	(	_	_	
24-20	5037-5041	Palo	_	_	
24-21	5042-5046	Alto	_	_	
24-22	5046-5047	,	_	_	
24-23	5048-5053	Calif	_	_	
24-24	5053-5054	.	_	_	
24-25	5054-5055	)	_	_	
24-26	5055-5056	.	_	_	
